Of interest are also hematologic malignancies; preliminary trials report impressive response rates in otherwise refractory disease [149], believed to be driven by both the inherent role of the PD-1/PD-L1 axis in the evasion of immunosurveillance in lymphoid tumors, particularly in those with a viral etiology [150], and by the presumed significance of PDL1 and PDL2 amplification in the biology of certain neoplasms such as Hodgkin lymphoma [22]. This evidence concerns the gene PDCD1LG2 and hematologic disorder.